Hemo Organic

Which are the latest news on Hemo Organic?

Why is Hemo Organic Ltd falling/rising?

As of 05-Sep, Hemo Organic Ltd's stock price is stable at 18.91 but has declined 14.20% over the past month. The stock faces downward pressure from poor trading activity, declining investor interest, and weak long-term fundamentals, despite a strong historical performance.

As of 05-Sep, Hemo Organic Ltd's stock price is currently stable at 18.91, showing no change (0.00%). However, the stock has experienced a decline of 14.20% over the past month, which contrasts with its year-to-date performance of +10.07% and a significant increase of +93.95% over the past year. <BR><BR>Despite the positive long-term returns, the stock is underperforming today, having fallen by 4.48% compared to its sector. This underperformance is compounded by erratic trading patterns, as the stock did not trade on 4 out of the last 20 days and has not traded at all in the last 10 days. Additionally, there has been a notable decrease in investor participation, with delivery volume dropping by 89.57% against the 5-day average.<BR><BR>The company's fundamentals also raise concerns; it has a negative book value of Rs 0.93 crore and has shown poor long-term growth, with net sales growing at an annual rate of only 38.20% and operating profit stagnating at 0% over the last five years. Furthermore, while the stock has generated impressive returns over the past year, its profits have plummeted by 94%, indicating a significant risk associated with its current valuation.<BR><BR>In summary, Hemo Organic Ltd's stock is facing downward pressure due to a combination of poor trading activity, declining investor interest, and weak long-term fundamentals, despite its historical performance.

Who are in the management team of Hemo Organic?

The management team of Hemo Organic includes Dineshbhai S Patel (Chairman & Managing Director), Sonal D Patel (Executive Director), Krushanakant R Patel (Independent Director), Sanjeev Lodha (Additional Independent Director), Siyona Jhnawar (Director), and Nishita Mayank Sanghvi (Company Secretary).

The management team of Hemo Organic includes the following individuals:<BR><BR>1. **Dineshbhai S Patel** - Chairman & Managing Director<BR>2. **Sonal D Patel** - Executive Director<BR>3. **Krushanakant R Patel** - Independent Director<BR>4. **Sanjeev Lodha** - Additional Independent Director<BR>5. **Siyona Jhnawar** - Director<BR>6. **Nishita Mayank Sanghvi** - Company Secretary<BR><BR>If you have any more questions about Hemo Organic or its operations, feel free to ask!

What does Hemo Organic do?

Hemo Organic Ltd produces and sells white coal and ayurvedic medicines, operating as a Micro Cap company. Founded in 1992, it transitioned from chemical manufacturing and currently reports a market cap of INR 7 Cr with no recent net profit.

Overview:<BR>Hemo Organic Ltd is engaged in the production and sale of white coal and ayurvedic medicines, operating within the Trading & Distributors industry and classified as a Micro Cap company.<BR><BR>History:<BR>Incorporated in August 1992, Hemo Organic Ltd was formerly known as Dinesh Allorga Limited. The company initially focused on manufacturing chemicals but discontinued this due to a pollution crisis. The latest quarterly results reported are for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>Market-cap value: INR 7 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A<BR>Industry P/E: 15<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -1.87<BR>Return on Equity: 78.00%<BR>Price to Book: -6.90<BR><BR>Contact Details:<BR>Address: 8-A Gulnar Chinar-Gulnar Apart, V V Nagar Road Anand Gujarat : 388001<BR>Tel: 91-2692-248535<BR>Email: drdineshpatel@rediffmail.com<BR>Website: http://www.hemoorganic.com

Who are the peers of the Hemo Organic?

Hemo Organic's peers include Mystic Electron, Sword-Edge Comm., Sirohia & Sons, Nyssa Corp., Ganon Products, Modella Woollens, Enterprise Intl., Oswal Yarns, and Priya. Hemo Organic leads with a 1-year return of 111.28%, while Ganon Products has the lowest return at -39.50%.

Peers: The peers of Hemo Organic are Mystic Electron., Sword-Edge Comm., Sirohia & Sons, Nyssa Corp., Ganon Products, Modella Woollens, Enterprise Intl., Oswal Yarns, and Priya.<BR><BR>Quality Snapshot: Excellent management risk is observed at Ganon Products, while Below Average management risk is found at Sword-Edge Comm., Nyssa Corp., Enterprise Intl., and Oswal Yarns, and the rest have management risks that do not qualify. Growth is rated as Good for Ganon Products, Below Average for Sword-Edge Comm., Nyssa Corp., Enterprise Intl., and Oswal Yarns, and the rest do not qualify. Capital Structure is rated as Excellent for Ganon Products, Good for Nyssa Corp., Below Average for Sword-Edge Comm., Enterprise Intl., and Oswal Yarns, and the rest do not qualify.<BR><BR>Return Snapshot: Hemo Organic has the highest 1-year return at 111.28%, while Ganon Products has the lowest at -39.50%. Hemo Organic's return significantly outperforms Ganon Products. Additionally, the six-month returns for Ganon Products, Oswal Yarns, and Enterprise Intl. are negative.

How big is Hemo Organic?

As of 31st August, Hemo Organic Ltd has a market capitalization of 7.00 Cr, with recent net sales of 0.93 Cr and a net profit loss of 0.77 Cr. Shareholder's funds were 0.13 Cr, and total assets were 4.46 Cr as of March 2026.

As of 31st August, Hemo Organic Ltd has a market capitalization of 7.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Hemo Organic reported Net Sales of 0.93 Cr. However, it experienced a loss of 0.77 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2026, where Shareholder's Funds amounted to 0.13 Cr and Total Assets were reported at 4.46 Cr.

Should I buy, sell or hold Hemo Organic Ltd?

Are Hemo Organic Ltd latest results good or bad?

Hemo Organic Ltd's latest results are concerning, showing a net loss of ₹0.51 crores in Q4 FY26, down from a profit of ₹0.37 crores last year, with revenue dropping 61.41% year-on-year. The company faces severe operational challenges and has a negative book value, indicating significant financial instability.

Hemo Organic Ltd's latest results are quite concerning. In Q4 FY26, the company reported a net loss of ₹0.51 crores, a significant decline from a profit of ₹0.37 crores in the same quarter last year. Additionally, revenue plummeted by 61.41% year-on-year to just ₹0.93 crores, marking a troubling trend after three consecutive quarters of zero sales.<BR><BR>The operating margin also deteriorated sharply, falling to -31.18% compared to a positive margin of 5.81% in the previous year. This indicates severe operational distress, as the company is struggling to manage its costs effectively while generating minimal revenue.<BR><BR>Moreover, Hemo Organic has a negative book value of ₹-0.44 per share, reflecting complete equity erosion, and its financial stability is in serious doubt. The company's operational challenges, combined with a lack of institutional investor confidence, suggest a very risky investment environment.<BR><BR>Overall, the results paint a grim picture of Hemo Organic's financial health, indicating that the company is facing significant operational and financial challenges.

When is the next results date for Hemo Organic Ltd?

The next results date for Hemo Organic Ltd is 29 May 2026.

The next results date for Hemo Organic Ltd is scheduled for 29 May 2026.

How has been the historical performance of Hemo Organic?

Hemo Organic has shown significant financial improvement from March 2024 to March 2025, with net sales rising from 0.02 Cr to 2.41 Cr and a turnaround in profitability, achieving a profit after tax of 0.16 Cr. However, the company faces challenges with increased total liabilities, which rose to 4.70 Cr.

Answer:<BR>The historical performance of Hemo Organic shows significant fluctuations in financial metrics over the years, particularly from March 2019 to March 2025.<BR><BR>Breakdown:<BR>Hemo Organic's net sales have seen a notable increase from Mar'24 at 0.02 Cr to Mar'25 at 2.41 Cr, marking a substantial growth. However, the total expenditure also rose sharply to 2.46 Cr in Mar'25 from 0.27 Cr in Mar'24, leading to an operating profit (PBDIT) of 0.02 Cr in Mar'25, a recovery from a loss of 0.25 Cr in the previous year. The profit before tax improved to 0.03 Cr in Mar'25, compared to a loss of 0.26 Cr in Mar'24, and the profit after tax turned positive at 0.16 Cr, reversing from a loss of 0.26 Cr. Despite these improvements, the company's total liabilities increased to 4.70 Cr in Mar'25 from 0.92 Cr in Mar'24, while total assets also rose to 4.70 Cr. The book value per share adjusted to -0.44 in Mar'25, an improvement from -0.91 in Mar'24. The earnings per share (EPS) showed a positive shift to 0.46 in Mar'25 from -0.75 in Mar'24, indicating a recovery in profitability. Overall, while Hemo Organic has made strides in revenue and profit metrics, it continues to face challenges with its liabilities and book value.

Who are the top shareholders of the Hemo Organic?

The top shareholders of Hemo Organic include Dineshbhai Shanabhai Patel with 15.49%, and the Indian Clearing Corporation Limited at 8.08%. Individual investors collectively own 71.11% of the shares, with no institutional holdings or pledged promoter shares reported.

The top shareholders of Hemo Organic include Dineshbhai Shanabhai Patel, who holds the largest stake at 15.49%. The highest public shareholder is the Indian Clearing Corporation Limited, with an ownership of 8.08%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 71.11% of the shares. There are no institutional holdings or pledged promoter shares reported.

Is Hemo Organic overvalued or undervalued?

As of April 1, 2024, Hemo Organic's valuation has shifted to risky due to overvaluation indicated by a PE ratio of 3.75 and poor performance compared to peers, with its stock declining 83.96% over the past three years versus a 49.13% increase in the Sensex.

As of 1 April 2024, Hemo Organic's valuation grade has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued based on its current metrics, with a PE ratio of 3.75, an EV to EBIT of -5.22, and a PEG ratio of 0.02, all of which suggest significant financial distress and poor profitability.<BR><BR>In comparison to its peers, Hemo Organic's valuation stands out negatively against companies like Altius Telecom, which has a PE ratio of 52.97 and is rated very attractive, and Sagility India, which is rated fair with a PE of 33.73. The stark contrast in these ratios highlights Hemo Organic's struggles within the trading and distribution industry. Additionally, the company's stock performance has lagged behind the Sensex, particularly over the past three years, where it has declined by 83.96% compared to a 49.13% increase in the index.

What is the technical trend for Hemo Organic?

As of June 2, 2025, Hemo Organic's trend is sideways with mixed signals: while the weekly and monthly MACD and Bollinger Bands show mild bullishness, daily moving averages indicate short-term weakness, resulting in overall market indecision.

As of 2 June 2025, the technical trend for Hemo Organic has changed from mildly bullish to sideways. The weekly MACD remains mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. However, the daily moving averages are mildly bearish, suggesting short-term weakness. The Bollinger Bands are bullish on both weekly and monthly time frames, which supports the overall bullish sentiment. The KST shows a mixed picture with weekly mildly bullish and monthly mildly bearish readings. Both the Dow Theory and RSI indicate no clear trend. Overall, the current stance is neutral with mixed signals, reflecting indecision in the market.

Has Hemo Organic declared dividend?

No Dividend History Available